In the past week, CLDX stock has gone up by 4.20%, with a monthly gain of 3.72% and a quarterly surge of 1.04%. The volatility ratio for the week is 1.87%, and the volatility levels for the last 30 days are 3.51% for Celldex Therapeutics Inc The simple moving average for the past 20 days is 0.87% for CLDX’s stock, with a -19.63% simple moving average for the past 200 days.
Is It Worth Investing in Celldex Therapeutics Inc (NASDAQ: CLDX) Right Now?
CLDX has 36-month beta value of 1.14. Analysts have mixed views on the stock, with 10 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CLDX is 64.51M, and currently, short sellers hold a 12.98% ratio of that float. The average trading volume of CLDX on June 13, 2025 was 868.55K shares.
CLDX) stock’s latest price update
Celldex Therapeutics Inc (NASDAQ: CLDX)’s stock price has decreased by -0.34 compared to its previous closing price of 20.42. However, the company has seen a 4.20% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-12 that HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.
Analysts’ Opinion of CLDX
Many brokerage firms have already submitted their reports for CLDX stocks, with Canaccord Genuity repeating the rating for CLDX by listing it as a “Buy.” The predicted price for CLDX in the upcoming period, according to Canaccord Genuity is $64 based on the research report published on April 28, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CLDX reach a price target of $46. The rating they have provided for CLDX stocks is “Overweight” according to the report published on March 20th, 2025.
UBS gave a rating of “Buy” to CLDX, setting the target price at $44 in the report published on February 13th of the current year.
CLDX Trading at 5.80% from the 50-Day Moving Average
After a stumble in the market that brought CLDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.70% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLDX starting from Marucci Anthony S, who purchase 11,500 shares at the price of $26.82 back on Nov 11 ’24. After this action, Marucci Anthony S now owns 40,284 shares of Celldex Therapeutics Inc, valued at $308,430 using the latest closing price.
Martin Samuel Bates, the SVP AND CFO of Celldex Therapeutics Inc, sale 17,172 shares at $35.42 during a trade that took place back on Jun 14 ’24, which means that Martin Samuel Bates is holding 28,125 shares at $608,315 based on the most recent closing price.
Stock Fundamentals for CLDX
Current profitability levels for the company are sitting at:
- -28.74 for the present operating margin
- 0.79 for the gross margin
The net margin for Celldex Therapeutics Inc stands at -23.66. The total capital return value is set at -0.31. Equity return is now at value -23.20, with -22.24 for asset returns.
Based on Celldex Therapeutics Inc (CLDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -50.03.
Currently, EBITDA for the company is -191.9 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 176.93. The receivables turnover for the company is 7.1for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.67.
Conclusion
To put it simply, Celldex Therapeutics Inc (CLDX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
